Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec(TM)).
10.5021/ad.2011.23.S3.S360
- Author:
Ah Young CHO
1
;
Dae Hun KIM
;
Myung IM
;
Young LEE
;
Young Joon SEO
;
Jeung Hoon LEE
Author Information
1. Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea. jhoon@cnu.ac.kr
- Publication Type:Case Report
- Keywords:
Imatinib mesylate;
Pityriasis rosea
- MeSH:
Benzamides;
Drug Eruptions;
Gastrointestinal Stromal Tumors;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Piperazines;
Pityriasis;
Pityriasis Rosea;
Pyrimidines;
Imatinib Mesylate
- From:Annals of Dermatology
2011;23(Suppl 3):S360-S363
- CountryRepublic of Korea
- Language:English
-
Abstract:
Imatinib mesylate (Gleevec(TM), STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.
